Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20®) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment. (more)

A swatch of hair, so thick and tangled it could have belonged to man or bear, has provided answers about a mysterious culture and its origins half a world away. (more)

Among scientists, 84-year-old Arno Motulsky is known as the “father of pharmacogenomics.” In 1957, Dr. Motulsky, a medical doctor and researcher at the University of Washington, published an article reporting that two drugs had negative interactions with enzymes produced by certain human genes. Might this be true of other pharmaceuticals, Dr. Motulsky wondered? His question set off a revolution in research. Dr. Motulsky, who grew up Jewish in Nazi Germany, barely made his way out of wartime Europe and to safety in America. (more)

The German parliament voted Friday in favour of relaxing legislation on stem cell research after months of heated debate, but stopped short of allowing stem cells to be cultivated in Germany. (more)

Scientists for the first time have used gene therapy to dramatically improve sight in people with a rare form of blindness, a development experts called a major advance for the experimental technique. (more)

Americans may be much more willing to get genetic tests showing predisposition to diseases with this week's expected final passage by Congress of a bill barring discrimination based on one's genetics, experts say. (more)

infoQuant Ltd brings microarray technology closer to clinical use with its latest release of copy number analysis and interpretation software oneClickCGHTM and CGH FusionTM for microarray-based comparative genomic hybridization tests (array CGH). (more)